TBio-4101

BIOLOGICAL3 trials

Sponsors

Turnstone Biologics, Corp., H. Lee Moffitt Cancer Center and Research Institute

Conditions

Acral MelanomaBreast CancerColorectal CancerConjunctival MelanomaCutaneous MelanomaHead and Neck Squamous Cell CarcinomaIris MelanomaMetastatic Melanoma

Phase 1

A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors

TerminatedNCT05576077

Turnstone Biologics, Corp.Breast Cancer, Colorectal Cancer, Cutaneous Melanoma +3

Start: 2023-01-17End: 2025-02-24Updated: 2025-03-10

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

CompletedNCT05628883

H. Lee Moffitt Cancer Center and Research InstituteAcral Melanoma, Conjunctival Melanoma, Cutaneous Melanoma +7

Start: 2022-11-22End: 2025-03-06Updated: 2026-04-02

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

Active, not recruitingNCT06236425

H. Lee Moffitt Cancer Center and Research InstituteMetastatic Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck

Start: 2024-03-14End: 2026-08-01Updated: 2026-04-01

Related Papers

A phase 1b study of tbio-4101 (autologous selected and expanded tumor-infiltrating lymphocytes [TILs]) with pembrolizumab in patients with anti-PD-1–resistant, advanced head and neck squamous cell carcinoma (aHNSCC).

Journal of Clinical Oncology2024-06-012 citations